logo

For the Inventor, By the Inventor

Como, Italy

Claudio Pietra

This inventor holds 26 USPTO granted patents and 4 published patent applications and 14 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Helsinn Healthcare Sa, Turboden, S.p.a., Anacardio Ab. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudio Pietra. Retrieved from https://idiyas.com/inventor/claudio-pietra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 26 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 31(Granted Patents)


Location History:

  • Como, IT (2013 - 2024)
  • Brescia, IT (2016 - 2024)

Company Filing History:

goldMedal21 out of 70 
 
Helsinn Healthcare Sa
 patents
silverMedal3 out of 16 
 
Turboden, S.p.a.
 patents
bronzeMedal2 out of 2 
 
Anacardio Ab
 patents
4. 1 out of 11 
 
Turboden S.r.l.
 patents
5. 1 out of 834,708 
Other
 patents
where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Inotropic Agents
Ghrelin Agonist
Organic Rankine Cycle
Asymmetric Ureas
Emesis Treatment
Piperazine Derivatives
Pharmaceutical Applications
Therapeutic Combinations
Chloromethyl Dialkylphosphates
Fumarate Salts
Neurokinin Receptor Modulators
26 patents (USPTO):Explore Patents
1. 12648941 - Piperidine urea derivatives for use as inotropic agents (2026-06-09),
2. 12569476 - Piperidine urea derivatives for use as inotropic agents (2026-03-10),
3. 12440485 - Centrally-active ghrelin agonist and medical uses thereof (2025-10-14),
4. 12071421 - Process for the synthesis of substituted chloromethyl dialkylphosphates (2024-08-27),
5. 12005056 - Centrally-active ghrelin agonist and medical uses thereof (2024-06-11),
6. 11976575 - Cascade organic Rankine cycle plant (2024-05-07),
7. 11884646 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof (2024-01-30),
8. 11802494 - Optimized cascade organic Rankine cycle (2023-10-31),
9. 11312698 - Fosnetupitant chloride hydrochloride having improved stability (2022-04-26),
10. 11299472 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof (2022-04-12),
11. 10717721 - Substituted piperaziniums for the treatment of emesis (2020-07-21),
12. 10577384 - Substituted asymmetric ureas as modulators of ghrelin receptor activity (2020-03-03),
13. 10501479 - Benzenesulfonyl-asymmetric ureas and medical uses thereof (2019-12-10),
14. 10407390 - Asymmetric ureas and medical uses thereof (2019-09-10),
15. 10247047 - Control method for an organic rankine cycle (2019-04-02),

Title: Innovations by Claudio Pietra: Pioneering Patents and Collaborations

Introduction

Claudio Pietra, a prominent inventor based in Como, Italy, has made significant contributions to the field of pharmaceuticals through his innovative patents. With a portfolio of 19 patents, his work focuses primarily on compounds that serve vital medical purposes, particularly in the treatment of conditions mediated by the ghrelin receptor and other significant chemical processes.

Latest Patents

Among his latest patents is a groundbreaking process for the synthesis of substituted chloromethyl dialkylphosphates. This invention details compounds, including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, which are effective in preventing and treating chemotherapy-induced emesis. The methodology includes a complex reaction involving dialkylphosphate salts and chloroiodomethane, positioning it as a significant advancement in pharmaceutical chemistry.

Another noteworthy patent is related to a centrally-active ghrelin agonist, a new compound that exhibits a remarkable ability to cross the blood-brain barrier and activate ghrelin receptors within the central nervous system. This compound has shown promise in treating neurotoxic damage and conditions that necessitate a reduction in heart rate. Its pharmacological activity at low to moderate doses reveals a favorable therapeutic index, underscoring its potential impact on medicine.

Career Highlights

Claudio Pietra’s career includes valuable experience with Helsinn Healthcare SA, where he has not only contributed to the development of innovative drugs but has also shaped his expertise in the medicinal chemistry domain. His successful patent portfolio illustrates his commitment to advancing therapeutic solutions through invention.

Collaborations

Throughout his professional journey, Pietra has collaborated with notable individuals like Claudio Giuliano and Silvina Garcia Rubio. These partnerships have bolstered the innovation process, enabling the synthesis of groundbreaking compounds aimed at addressing complex health issues.

Conclusion

Claudio Pietra stands out as a distinguished inventor whose work continues to influence the pharmaceutical industry. With a solid foundation built on 19 patents and fruitful collaborations, his innovations pave the way for new treatment options that hold the promise of improving patient health and quality of life.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…